Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis

Pediatric Dermatology

Volumn 24, Issue 3, 2007, Pages 289-295

  Eichenfield, Lawrence F ^a   Basu, Sarmistha ^b   Calvarese, Barry ^b   Trancik, Ronald J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Dow Pharmaceutical Sciences Inc   (United States)

^c SkinMedica Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESONIDE; HYDROCORTISONE; TETRACOSACTIDE;

ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; BURNING SENSATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ECCHYMOSIS; FEMALE; HORMONAL REGULATION; HUMAN; HYDROGEL; HYPERTRICHOSIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFANT; LOCAL SKIN REACTION; MALE; MULTICENTER STUDY; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; SKIN ATROPHY; SKIN SENSITIZATION; STEROID THERAPY; STRIA; SUPERINFECTION; SWEAT GLAND DISEASE; SYMPTOMATOLOGY; TELANGIECTASIA;

ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; COSYNTROPIN; DERMATITIS, ATOPIC; DESONIDE; FEMALE; HORMONES; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFANT; MALE; PITUITARY-ADRENAL SYSTEM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34249822834     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2007.00405.x     Document Type: Article

References (12)

1. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003 112 (6 Suppl. S118 S127.
2. Laughter D, Istvan JA, Tofte SJ et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000 43 : 649 655.
3. IMS Health U.S. prescription data January 2004-August 2006.
4. Protopic® (tacrolimus ointment 0.03%, tacrolimus ointment 0.1% [for dermatologic use only]). Package insert. Deerfield : Fujisawa Healthcare, Inc., Revised 2006.
5. Elidel® (pimecrolimus cream 1% for dermatologic use only). Package insert. Wehr, Germany : Novartis Pharma GmbH, Revised 2006.
6. Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002 46 : 387 393.
7. Phillips B, Sanen F, Leeling J et al. The physical, animal and human pharmacologic and toxicologic properties of desonide, a new, topically active, antiinflammatory steroid. Toxicol Appl Pharmacol 1971 20 : 522 537.
8. Lucky AW, Grote GD, Williams JL et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 1997 59 : 151 153.
9. Wong VK, Fuchs B, Lebwohl M. Overview on desonide 0.05%: a clinical safety profile. J Drugs Dermatol 2004 3 : 393 397.
10. Jorizzo J, Levy M, Lucky A et al. Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 1995 33 : 74 77.
11. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermvenereol 1980 92 : 44 47.
12. Hebert AA, Cook-Bolden FE, Basu S, Calvarese B, Trancik RJ, Desonide Hydrogel Study Group. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol 2007 6 : 175 181.